Slate Path Capital LP Arrowhead Pharmaceuticals, Inc. Call Options Transaction History
Slate Path Capital LP
- $6.33 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARWR
# of Institutions
295Shares Held
91.1MCall Options Held
155KPut Options Held
426K-
Black Rock Inc. New York, NY15.7MShares$293 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$229 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.89MShares$166 Million2.59% of portfolio
-
State Street Corp Boston, MA6.35MShares$119 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.57MShares$66.9 Million0.04% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $1.98B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...